This document serves as a formal corrigendum for the research article titled "Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR," originally published in Frontiers in Pharmacology. While the primary purpose of this update is to rectify an administrative error in the funding acknowledgment, it provides an opportunity to revisit the significant pharmacological insights regarding bone health and drug repurposing presented in the study.
Abstract
In the original publication, an error was identified in the Funding statement. The grant number for the National Natural Science Foundation of China was incorrectly listed as 81372915. The correct grant number is 81371915. The authors have clarified that this administrative correction does not alter the scientific findings, experimental data, or the overarching conclusions of the research.
Addressing Post-Menopausal Osteoporosis
The underlying study addresses the critical challenge of post-menopausal osteoporosis. This condition is driven by a hormonal imbalance—specifically the drop in estrogen—that disrupts the natural cycle of bone remodeling. In this state, osteoclasts (cells responsible for bone resorption) become overactive, outpacing the bone-building activity of osteoblasts. The result is a progressive loss of bone mineral density and an increased susceptibility to fractures.
The Potential of Drug Repurposing: Meclizine
A central contribution of this research is the exploration of Meclizine, an FDA-approved antihistamine traditionally used to treat motion sickness and vertigo. By identifying Meclizine's secondary role in bone preservation, the study exemplifies the value of drug repurposing. Utilizing established medications for new therapeutic indications can significantly accelerate the transition from laboratory discovery to clinical application, as the safety profiles of these drugs are already well-documented.
Molecular Mechanism: The PXR Pathway
The researchers investigated the molecular pathways through which Meclizine exerts its protective effects. They identified the Pregnane X Receptor (PXR) as a key mediator. While PXR is primarily recognized for its role in the liver as a sensor for detoxifying foreign substances, this study demonstrates its importance in skeletal integrity.
Key insights into the mechanism include:
- Upregulation of PXR: Meclizine treatment leads to the upregulation of PXR.
- Inhibition of Osteoclastogenesis: The activation of the PXR pathway inhibits the process by which precursor cells differentiate into mature, bone-destroying osteoclasts.
- Multifaceted Action: The study notes that the prevention of bone loss is "partially" due to PXR, suggesting that Meclizine may interact with additional signaling pathways to maintain bone mass.
Conclusion
The findings of the original study remain valid: Meclizine successfully prevents bone loss in ovariectomized animal models (the standard model for human menopause) and effectively slows the formation of osteoclasts. This corrigendum ensures the accuracy of the academic record regarding the support provided by the National Natural Science Foundation of China (Grant 81371915) while reaffirming the study's contribution to the field of osteopharmacology.
Summary updated